No Data
No Data
Jazz Pharmaceuticals Balances Growth and Challenges in Earnings Call
Top Gap Ups and Downs on Wednesday: BABA, DIS, MRVL and More
Express News | Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock.
Express News | Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock